Abbott Laboratories (ABT): analysis and signal as of September 6, 2026
In short
The signal for Abbott Laboratories is moderate, with a score of -0.5. The upward revision to BPA guidance supports the thesis, but negative intraday flows and regular disposals by executives limit its strength.
- Current signal
- moderate (vote 3/3)
- Deterministic score
- -0.5 → signal expected by the scale : weak (September 10, 2026)
- Layers
- fundamentals : positive, price : neutral, risks : positive
Triggered rules
| Rule | Weight |
|---|---|
| penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE | -1.0 |
| moderately favors an asset with robust operating profitability (RMW factor), cross-check with accounting quality (possible manipulation) | +0.5 |
Thesis
Abbott combines comparable growth of 6,5 to 7,5 % and BPA guidance raised to 5,45-5,60 USD, with sector diversification presented as protection against the complacency observed on the Cboe. The current price is 108,33 USD. The expansionary macroeconomic regime favors defensive healthcare, but pressure on rate-sensitive stocks and the positive US 10-2 yield curve slope constrain valuation. Negative intraday flows and executive disposals therefore temper the operational outlook.
Bull case
The 2026 guidance was raised on 16/07/2026 to 5,45-5,60 USD in adjusted diluted BPA. The bullish argument also draws on S1 2026 revenue of 6,60 Md USD (+14 %), 2,1 Md USD returned to shareholders and FDA approval of the first glucose monitoring device on 27/08/2026. The 2026e PER of 20,4x complements these valuation considerations.
Bear case
Intraday flows of -18,1 % over 6 months are interpreted in the analysis as a sign of institutional disposals. Aggregate US short interest of 1,31 % (z +0,29) is associated with insufficient hedging. Litigation concerning spinal cord stimulators, with a JPML decision expected in autumn 2026, represents a further uncertainty, while executives regularly dispose of 20 000 shares per quarter.
Scenarios
The bullish scenario is assigned a probability of 40 %. The base scenario, weighted at 45 %, describes sideways price movement in the period preceding the quarterly results publication. The bearish scenario, weighted at 15 %, corresponds to a deterioration linked to an unfavorable JPML consolidation or a Cboe correction.
Risks
The identified risks concern spinal cord stimulator litigation, an unfavorable JPML consolidation and a Cboe correction. Interest rate sensitivity may weigh on valuation. Negative intraday flows and regular executive disposals also constitute sources of vulnerability in the analysis.
Market positioning (short sellers)
- Short interest / shares outstanding
- 1.19 %
- Days to cover
- 2.86
- Settlement date
- 2026-08-14
- Source
- FINRA (disseminated on 2026-08-26)
Upcoming catalysts
| Date | Description |
|---|---|
| Q3 2026 results and Libre 3 / Libre 4 trajectory. | |
| Cardiology Investor Conference. |
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| moderate (3/3) | not published | |
| moderate (single draw, outside the three-draw protocol) | unchanged | |
| moderate (single draw, outside the three-draw protocol) | unchanged |
Frequently asked questions
Why does the signal remain moderate despite the upward revision to guidance?
The upward revision to BPA guidance to 5,45-5,60 USD and comparable growth of 6,5 to 7,5 % support the operational thesis. However, intraday flows of -18,1 % over 6 months, regular executive disposals and interest rate sensitivity limit the strength of the signal. The stated score is -0.5.
What factors support the bullish argument?
The bullish argument rests on the 2026 guidance raised on 16/07/2026, S1 2026 revenue of 6,60 Md USD (+14 %) and 2,1 Md USD returned to shareholders. FDA approval of the first glucose monitoring device on 27/08/2026 complements these factors. The analysis also mentions a 2026e PER of 20,4x and sector diversification that supports the thesis.
What factors could lead to the bearish scenario?
The bearish scenario is associated with an unfavorable JPML consolidation in the spinal cord stimulator litigation or a Cboe correction. Its probability is 15 %. Negative intraday flows, regular executive disposals and pressure on rate-sensitive stocks constitute other sources of vulnerability cited in the analysis.
Sources
The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
- — 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits (SEC · 8-K)
- — 10-Q (SEC · 10-Q)
- — 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits (SEC · 8-K)
- — 10-Q (SEC · 10-Q)
- — 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; 5.03 Ame… (SEC · 8-K)
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on September 6, 2026; this page was completed on September 6, 2026 at 18:59 (UTC).
- Interests: no position in the stock analysed (ABT) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: AbbVie, Inc. (ABBV)
- All analysed stocks
- Public methodology